ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Drug Makers Push On With Alzheimer's Research After Setback

By Peter Loftus This week's failure of an experimental drug for Alzheimer's disease underscores the limitations on scientific understanding of the brain disorder, but drug companies are plowing ahead in search of new treatments because of the high medical need and potential financial payoff. Pfizer Inc. (PFE) and Johnson & Johnson (JNJ) announced Monday they would discontinue development of intravenously administered bapineuzumab after it failed to provide a benefit in a second late-stage clinical trial. It was the latest in a series of setbacks in the drug industry's attempt to find the first drug to halt or reverse Alzheimer's. But drug companies continue to study potential drugs for the disease, including Eli Lilly & Co. (LLY), Baxter International Inc. (BAX), Roche Holding AG (RHHBY), Merck & Co. (MRK) and Bristol-Myers Squibb Co. (BMY). Current treatments don't stop the progression of the underlying disease, which impairs memory and cognitive skills primarily in the elderly. About 5 million Americans are estimated to have Alzheimer's. The bapineuzumab failure further clouds the outlook for a similar drug developed by Lilly. The company is expected to report results later this month or in September of late-stage studies of solanezumab, which will help determine whether Lilly can submit it for regulatory approval or will drop development. Both bapineuzumab and solanezumab are antibodies designed to reduce a substance in the brain called amyloid. Scientists have hypothesized that the buildup of amyloid in the brain plays a role in Alzheimer's disease. There are certain differences between bapineuzumab and solanezumab--as Lilly has emphasized--and in the off chance that Lilly's drug succeeds, it could generate $23 billion in annual sales by 2020, Bernstein has estimated. But few analysts expect the Lilly drug to succeed, a view reinforced by the failure of bapineuzumab. If the Lilly drug fails, that leaves several other disease-modifying possibilities in the drug research pipeline that target amyloid in different ways or have other mechanisms. Roche also is studying an antibody that targets amyloid, among other approaches. Most of these, however, are likely several years away from reaching the market, assuming they are successful in clinical trials. "We will find therapies that change the course of Alzheimer's disease in the foreseeable future," said William H. Thies, chief medical and scientific officer of the Alzheimer's Association, which supports Alzheimer's research. "What I can't tell you is whether the first drug that will do that is going to be something we find in three, five, seven or 12 years. We don't really know which drug is going to be effective." Dr. Thies said it is too soon to make any conclusions about whether drug makers have been chasing the wrong target with the amyloid hypothesis. He said the expected presentation of full results of the trials of bapineuzumab and solanezumab later this year will shed more light on the matter. If the antibody drugs failed to significantly reduce amyloid concentrations, then it is possible that the amyloid hypothesis remains intact and other approaches to reducing amyloid might still work, he said. However, if the drugs did reduce amyloid and still failed to show a benefit, then it's possible that reducing amyloid isn't the right approach and another target is needed for a successful drug, or that patients need to be treated earlier in the course of the disease, he said. Other Alzheimer's efforts include: --Baxter International expects late-stage, or Phase 3, clinical results for Gammagard in Alzheimer's patients. Gammagard is currently used to treat patients with immunodeficiency diseases, but it is thought to contain antibodies that could remove amyloid from the brain. One caveat: Even if the clinical results are positive, Baxter will have to figure out how to manufacture enough of the product because it is derived from blood plasma. --Merck expects to begin clinical studies in Alzheimer's patients by year end for MK-8931, its so-called "BACE" inhibitor, short for B-amyloid precursor protein site cleaving enzyme. The drug is designed to essentially prevent the buildup of amyloid in the brain, rather than reduce amyloid after it has built up. Darryle D. Schoepp, senior vice president and franchise head for neuroscience at Merck Research Laboratories, said "there's strong genetic data" suggesting that reducing production of amyloid peptides at their source in the brain may protect against Alzheimer's disease. Other companies including Lilly also are developing BACE inhibitors. --Roche's crenezumab, an antibody targeting amyloid, is being studied in cognitively healthy people in Colombia who are likely to develop Alzheimer's due to their genetic history, to test whether it can prevent the disease. Roche's Genentech unit is collaborating with the Banner Alzheimer's Institute and the National Institutes of Health on the trial. --Cancer drug bexarotene was shown to reverse Alzheimer's symptoms in mice. A startup company called ReXceptor Therapeutics plans to begin human testing to determine whether the mice findings translate to humans. The caveat: Positive findings in animal studies often fail to translate into human benefits. --Another hypothesis for Alzheimer's is that so-called tau proteins in brain cells malfunction, leading to Alzheimer's symptoms. TauRx Pharmaceuticals Ltd. is running clinical trials of a drug that targets the tau proteins. Merck and other companies also are exploring compounds that target tau. Write to Peter Loftus at peter.loftus@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
11/17/201411:41:20U.S. Stocks Bounce Back from Early Loses
11/17/201405:11:44Pfizer, Germany's Merck to Develop Tumor Treatment -- Update
10/27/201416:37:41MARKET SNAPSHOT: Energy Stocks Sap S&P 500
10/27/201414:06:16MARKET SNAPSHOT: U.S. Stocks Retreat; Energy Stocks Sell Off
10/27/201411:51:27MARKET SNAPSHOT: U.S. Stock Retreat; Energy Stocks Sell Off
10/27/201411:47:43MARKET SNAPSHOT: U.S. Stock: Futures Fall; Focus On Fed
10/27/201411:40:15MARKET SNAPSHOT: Stock Futures Flatten After Weak German Data;...
10/26/201405:18:37MARKET SNAPSHOT: Energy, Health Care Earnings To Dominate Week
10/02/201410:57:10EUROPE MARKETS: European Stocks Flop As ECB's Draghi Talks Stimulus
10/02/201410:10:14EUROPE MARKETS: European Stocks Fall As ECB's Draghi Talks Stimulus
10/02/201408:45:12EUROPE MARKETS: European Stocks Fall; ECB Watched For Stimulus...
10/02/201405:53:22EUROPE MARKETS: European Stocks Fall; ECB Stimulus Details On...
10/02/201403:50:10Bayer Sells $7 Billion Bond
10/01/201418:10:29Esperion Reports Favorable Cholesterol Drug Data
10/01/201417:58:21Esperion Reports Favorable Cholesterol Drug Data -- Update
09/29/201417:56:12Doctor Group Backs Implantable Devices to Prevent Teen Pregnancies
09/24/201421:28:09Correction to Dow Index Overseers Correction
09/24/201421:08:41Correction to Dow Index Overseers Story
09/24/201419:57:00Dow Index Overseers Make It Official: U.S. Firms Only
09/24/201406:29:39German Data Keep European Stocks Recovery in Check -- Update

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad